<DOC>
	<DOCNO>NCT01305746</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety A-623 subject SLE .</brief_summary>
	<brief_title>A Trial Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Completed treatment period specify study ANSLE3321 enrol study ANSLE3321 prior November 30 , 2010 Developed new medical disease condition make subject unsuitable study opinion Investigator , include interference write informed consent , study evaluation , completion , and/or procedure Pregnant nursing Any prior administration Bcell modulate therapy A623 Received cyclophosphamide , cyclosporine , antiTNF alpha therapy , transfusion , plasmapheresis plasma exchange , IV immunoglobulin , live vaccine accord list washout period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>Lupus Erythematosus , Systemic</keyword>
	<keyword>A-623</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Blisibimod</keyword>
</DOC>